Rezolute (NASDAQ:RZLT) Stock Gets Price Target Increase from Wedbush

Rezolute (NASDAQ:RZLT – Get Free Report) had its target price boosted by stock analysts at Wedbush from $6.00 to $10.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush‘s price objective indicates a potential upside of 179.33% from the company’s previous close.

RZLT has been the subject of several other reports. Citizens Jmp increased their target price on shares of Rezolute from $11.00 to $15.00 and gave the stock a “market outperform” rating in a report on Tuesday, October 6th. Citigroup reaffirmed a “market outperform” rating on shares of Rezolute in a report on Thursday, October 15th. Zacks Research lowered shares of Rezolute from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 13th. HSBC raised shares of Rezolute to a “buy” rating in a research note on Friday, September 25th. Finally, HC Wainwright increased their price objective on shares of Rezolute from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, September 25th. Twelve investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $11.67.

View Our Latest Report on RZLT

Rezolute Price Performance

Shares of RZLT stock opened at $3.58 on Tuesday. Rezolute has a 1 year low of $1.07 and a 1 year high of $11.16. The firm has a fifty day moving average price of $4.05 and a 200-day moving average price of $3.93.

Rezolute (NASDAQ:RZLT – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.01. Sell-side analysts forecast that Rezolute will post -0.66 EPS for the current year.

Hedge Funds Weigh In On Rezolute

Hedge funds and other institutional investors have recently modified their holdings of the stock. AlphaCentric Advisors LLC boosted its position in shares of Rezolute by 4.5% during the third quarter. AlphaCentric Advisors LLC now owns 75,495 shares of the company’s stock worth $313,000 after acquiring an additional 3,240 shares during the last quarter. Auxano Advisors LLC bought a new stake in Rezolute in the 2nd quarter valued at $52,000. Sequoia Financial Advisors LLC bought a new stake in Rezolute in the 2nd quarter valued at $75,000. WINTON GROUP Ltd bought a new stake in Rezolute in the 2nd quarter valued at $88,000. Finally, ADAR1 Capital Management LLC lifted its stake in Rezolute by 51.7% in the 1st quarter. ADAR1 Capital Management LLC now owns 58,679 shares of the company’s stock worth $179,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors own 82.97% of the company’s stock.

About Rezolute

(Get Free Report)

Rezolute, Inc. is a clinical-stage biopharmaceutical company based in Redwood City, California. It develops treatments for rare diseases, with a focus on conditions that cause dangerously low blood sugar. The company’s lead drug candidate, ersodetug (formerly RZ358), is an investigational monoclonal antibody designed to modulate insulin-receptor signaling. Rezolute is studying it for congenital hyperinsulinism, a rare disorder in which the body produces too much insulin, and other forms of severe hypoglycemia.

Further Reading

Analyst Recommendations for Rezolute (NASDAQ:RZLT)

Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.